- Home
- DXST vs BIVI Comparison
DXST vs BIVI Comparison
Compare DXST & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXST
- BIVI
- Stock Information
- Founded
- DXST 2011
- BIVI 2013
- Country
- DXST China
- BIVI United States
- Employees
- DXST N/A
- BIVI N/A
- Industry
- DXST
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- DXST
- BIVI Health Care
- Exchange
- DXST NYSE
- BIVI Nasdaq
- Market Cap
- DXST 20.3M
- BIVI 18.8M
- IPO Year
- DXST 2025
- BIVI N/A
- Fundamental
- Price
- DXST $1.33
- BIVI $0.90
- Analyst Decision
- DXST
- BIVI Strong Buy
- Analyst Count
- DXST 0
- BIVI 1
- Target Price
- DXST N/A
- BIVI $30.00
- AVG Volume (30 Days)
- DXST 54.3K
- BIVI 230.4K
- Earning Date
- DXST 01-01-0001
- BIVI 05-13-2025
- Dividend Yield
- DXST N/A
- BIVI N/A
- EPS Growth
- DXST 13.11
- BIVI N/A
- EPS
- DXST 0.14
- BIVI N/A
- Revenue
- DXST $11,542,292.00
- BIVI N/A
- Revenue This Year
- DXST N/A
- BIVI N/A
- Revenue Next Year
- DXST N/A
- BIVI N/A
- P/E Ratio
- DXST $8.91
- BIVI N/A
- Revenue Growth
- DXST 22.18
- BIVI N/A
- 52 Week Low
- DXST $0.86
- BIVI $0.80
- 52 Week High
- DXST $5.74
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- DXST N/A
- BIVI 37.09
- Support Level
- DXST N/A
- BIVI $0.99
- Resistance Level
- DXST N/A
- BIVI $1.10
- Average True Range (ATR)
- DXST 0.00
- BIVI 0.10
- MACD
- DXST 0.00
- BIVI 0.01
- Stochastic Oscillator
- DXST 0.00
- BIVI 34.07
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.